Summary
This Nature study (2018) reports that transforming growth factor beta (TGFβ) attenuates anti-tumour immunity by promoting T cell exclusion from the tumour microenvironment, thereby limiting response to PD-L1 checkpoint blockade. The authors demonstrate that TGFβ signalling suppresses T cell infiltration through multiple mechanisms, as suggested by their analysis of patient samples and preclinical models. These findings suggest that combining TGFβ pathway inhibition with PD-L1 blockade may enhance immunotherapy efficacy in resistant tumours.
UK applicability
The mechanistic insights may inform development of combination immunotherapy strategies applicable to UK cancer treatment protocols, particularly for patients with TGFβ-driven immune exclusion. However, direct clinical translation would require validation in UK patient populations and integration with NHS treatment pathways.
Key measures
T cell infiltration density, TGFβ signalling activation, tumour response to anti-PD-L1 therapy, immune cell populations in tumour microenvironment
Outcomes reported
The study examined mechanisms of resistance to PD-L1 checkpoint inhibitor therapy, specifically investigating how transforming growth factor beta (TGFβ) contributes to T cell exclusion from tumours. The research measured tumour response, T cell infiltration, and TGFβ pathway activation in patient samples and preclinical models.
Topic tags
Dig deeper with Pulse AI.
Pulse AI has read the whole catalogue. Ask about this record, its theme, or how the findings apply to UK farming and policy — every answer cites the underlying studies.